Summary
- Altria Group Inc. and its subsidiaries remained highly durable in the US tobacco industry as its sales kept growing significantly despite the restriction on tobacco products in many cities.
- Its investment in AB SABMiller has been a huge factor that stimulated its non-operating income in the last two years.
- The dividend payment has been increasing and attracting a multitude of long-term investors over time.
- Its stock price is now leaving its low point. There may be a higher resistance and support level.
- The M&A deal with JUUL Labs Inc. and investment in Cronos Group will add value.
Altria Group Inc. (MO) remained formidable and versatile despite the challenges that have transpired in the industry. For many years, health organizations have been organizing campaigns against the massive production and purchase of combustible cigarettes in many states. Nevertheless, it supported the act though it might have posed a serious threat to its financial performance as many of its fellows had a hard time coping with it.
In the last 15 years, it did its best to withstand all these by diversifying itself and adapting with the changing condition of the market. Apparently, it kept soaring high as shown by its impressive revenue. Together with its subsidiaries, it continued to eat a huge part of the segment's pie and was expected to do so in the coming years since it just tied the knot with JUUL Labs and Cronos Group last quarter.
